 BEAMs novel CRISPR technology gives it a niche in a crowded and volatile market alongside other CRISPR companies trading at high valuations. While the standard CRISPR-cas9 approach cuts double-stranded DNA and to insert genetic sequences, base editing erases a point mutation and replaces with a new letter. 